The experiences of patients & care partners motivate us.
At Sage, identifying unmet patient needs drives our research and development focus. We seek to increase awareness and improve understanding of brain health disorders and integrate patient and care partner perspectives into every aspect of our work. Sage understands that brain health disorders affect not only individuals, but families, communities, and society. We engage with advocacy groups and those they serve to listen and learn from them as we rethink care and how to deliver it.
We are committed to developing new medicines to transform the lives of individuals with life-altering brain health disorders. As part of this mission, we conduct clinical trials to determine if our investigational medicines are safe and effective for individuals with a particular disease, disorder or condition which may allow us to seek the necessary regulatory approvals to provide wide access to these medicines.
We understand that, in some cases, individuals with serious diseases or conditions may not be eligible for clinical trials and may not have other treatment options. Under very limited circumstances, we will consider making investigational medicines available for qualifying patients to treat a serious disease or condition outside of a clinical trial. “Early access”, “expanded access” and “compassionate use” are terms that describe this type of access.